PROPHER: Quality-of-life feedback using patient-reported outcomes after treatment of parastomal hernia

ISRCTN ISRCTN32116071
DOI https://doi.org/10.1186/ISRCTN32116071
IRAS number 298207
Secondary identifying numbers CPMS 52007, BRUK334, IRAS 298207
Submission date
17/07/2023
Registration date
17/08/2023
Last edited
21/08/2023
Recruitment status
Recruiting
Overall study status
Ongoing
Condition category
Digestive System
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Record updated in last year

Plain English summary of protocol

Background and study aims
PROPHER stands for Patient Reported Outcomes after Parastomal Hernia Treatment. The overall aim of the PROPHER study is to see what the impact on the patient’s quality of life is from having treatment for a parastomal hernia. The study will also look at how parastomal hernias are treated, for example having an operation and any complications that happen in the first 30 days, or deciding to “watch and wait”. It will also look at whether there are any links between the way that a surgeon repairs a parastomal hernia and the outcomes.

What is a parastomal hernia? Stoma formation is often necessary after bowel surgery. A common complication of a stoma is a parastomal hernia (PSH) - caused by a weakness in the abdominal muscle which results in a local bulge next to or behind the stoma. A PSH can cause skin irritation, problems with getting a stoma bag to stick, as well as pain and other more serious complications such as bowel obstruction. These issues often have a negative impact on a patient’s quality of life.

What are patient-reported outcomes? Patient-reported outcome measures (PROMs) are questionnaires that measure the patient’s view of their own health. Questionnaires are completed before and after treatment so that healthcare professionals and researchers can see how the treatment has impacted the patient.

Who can participate?
Patients aged 18 years or above with a symptomatic parastomal hernia. This includes those referred to a colorectal surgeon for consideration of surgical treatment or seen by a clinical nurse specialist. Patients undergoing surgical treatment or conservative/watchful waiting are eligible for entry.

What does the study involve?
Participants will be asked to complete questionnaires about their parastomal hernia as well as information about how they feel at various stages throughout their treatment. These details will be collected at the start (baseline), at 3 months, 6 months and at 12 months. The hospital team will also record some additional information about the participant's medical history, and if patients have an operation as part of their treatment, they will record details about the surgery.

What are the possible benefits and risks of participating?
We do not expect any risk to study participants. Joining the study will not have any impact on patient care as participants will be receiving the same treatment they would if they do not join the study. Participants might find messages reminding them to complete the questionnaires a minor inconvenience given that the study follow-up period continues up to 12 months after joining the study.
There will not be any direct personal benefit to joining the study. However, the data collected from the study will translate into direct benefits for patients in the future. It is possible that a patient participating in PROPHER will not achieve successful PSH treatment during the lifetime of the study, or they will develop a new or recurrent PSH in the future. As such an individual may also be able to personally benefit from their involvement in the study.

Where is the study run from?
University of Birmingham (UK)

When is the study starting and how long is it expected to run for?
March 2021 to August 2028

Who is funding the study?
Bowel Research UK and the European Society of Coloproctology (ESCP)

Who is the main contact?
Rita Perry, r.perry.1@bham.ac.uk

Study website

Contact information

Dr Rita Perry
Scientific

Birmingham Centre for Observational and Prospective Studies
Public Health Building
University of Birmingham
Birmingham
B29 2TT
United Kingdom

ORCiD logoORCID ID 0000-0001-5284-8634
Phone +44 (0)121 414 9106
Email r.perry.1@bham.ac.uk
Prof Thomas Pinkney
Principal Investigator

Birmingham Clinical Trials Unit
Public Health Building
University of Birmingham
Birmingham
B29 2TT
United Kingdom

ORCiD logoORCID ID 0000-0001-7320-6673
Phone +44 (0)121 414 9012
Email thomas.pinkney@uhb.nhs.uk

Study information

Study designObservational cohort study
Primary study designObservational
Secondary study designCohort study
Study setting(s)Hospital, Internet/virtual, Medical and other records
Study typeQuality of life
Participant information sheet 43966_PIS_v5.0_21Jun2023.pdf
Scientific titlePatient Reported Outcomes after parastomal hernia treatment - a prospective international cohort study
Study acronymPROPHER
Study objectivesA prospective international cohort study of parastomal hernia (PSH) treatment, including both operative and non-operative interventions. A global network of clinicians and specialist nurses will collate detailed information on individual interventions used and short-term outcomes, then patients will provide their own medium and longer-term outcomes data including whether their treatment was successful, via a secure online/mobile phone-based system. The study will provide a wealth of contemporaneous information which will improve our ability to counsel patients and facilitate improved selection of appropriate and personalised interventions for those with a PSH.
Ethics approval(s)

Approved 04/04/2022, South Central - Hampshire B Research Ethics Committee (2 Redman Place, Stratford, London, E20 1JQ, United Kingdom; +44 (0)20 7104 8064; hampshireb.rec@hra.nhs.uk), ref: 22/SC/0060

Health condition(s) or problem(s) studiedParastomal hernia (PSH) treatment
InterventionPROPHER is an international multi-centre prospective cohort study. A global network of clinicians and specialist nurses will enrol adults over the age of 18 years with a symptomatic parastomal hernia (PSH) for which treatment or intervention is being sought. the study is observational only - no intervention will be decided by the study protocol and is instead as per treating clinician's decision.

Patients undergoing both operative and non-operative interventions will be included, and identical outcome measures obtained for both populations. These outcome measures of treatment success will be almost exclusively patient-reported up to one year after study and include quality of life, stoma-specific symptom scores and additional treatments including hospital admission. In addition, a modified MYMOP (Measure Yourself Medical Outcomes Profile) will be obtained at study entry and this entirely personalised outcome measure assessed individually at study exit (12 months). A decisional regret analysis will also be obtained at study exit.

Patients undergoing surgical intervention during the study period will have additional detailed information recorded about the operative techniques employed so we can assess any impacts, beneficial or otherwise, on patient-reported outcomes. If a patient in the conservative management arm undergoes surgical repair of their parastomal hernia during the 12-month follow-up period, they will automatically cross over into the surgical group.
Intervention typeOther
Primary outcome measureThis study will collect a range of clinical and patient-reported outcome measures. There is no explicit primary outcome measure.

Patient-reported outcomes:
1. Health-related quality of life reported by the participant using the SF-12 score at baseline and 3, 6 and 12 months post-enrolment
2. Stoma impact reported by the participant using the Stoma Impact Score at baseline and 3, 6 and 12 months post-enrolment
3. Impact of the key symptom or issue the patient is hoping will be improved by their PSH treatment assessed using the modified Measure Yourself Medical Outcomes Profile (MYMOP) at baseline and 12 months post-enrolment
4. Decisional regret assessed using the Decision Regret Scale at 12 months post-enrolment

Clinician-reported outcomes based on routinely collected data held in patient notes transcribed into electronic case report forms (eCRFs):
1. Patient demographics – including BMI, smoking status and comorbidities assessed using the online case report form (CRF) for the study at baseline
2. PSH details - including index operation, PSH characteristics and symptoms, previous treatments for this PSH - assessed using the online CRF at baseline
3. In those undergoing surgical repair:
3.1. Operation details – including technique employed, type and location of mesh placement (if appropriate) assessed using the online CRF at time of surgery
3.2. Short-term post-operation details assessed using the online CRF up to 30 days post-surgery, including:
3.2.1. Postoperative complications assessed using the Clavien-Dindo Scale
3.2.2. Postoperative complications assessed using the comprehensive complication index (CCI)
3.2.3. Length of stay
3.2.4. Unplanned re-operation
4. In those undergoing non-operative management:
4.1. Details of conservative treatment instigated, including support wear, physiotherapy, other advice given assessed using the online CRF at baseline
Secondary outcome measuresThere are no additional outcome measures
Overall study start date01/03/2021
Completion date15/08/2028

Eligibility

Participant type(s)Patient
Age groupAdult
Lower age limit18 Years
SexBoth
Target number of participantsPlanned Sample Size: 1500; UK Sample Size: 500
Key inclusion criteria1. Adult, aged 18 years and above.
2. A stoma formed from any part of the bowel – whole small bowel and colon, and of any format – including loop, end, double barreled, Abcarian, other
3. All treatments for PSH, including conservative (non-operative) treatment and surgical intervention. All types of surgical approach are included.
4. Elective presentations to outpatient services, including surgical, colorectal, stoma care team are included. Patients presenting primarily as an emergency with a symptomatic PSH requiring urgent intervention are also eligible for inclusion, providing informed consent can be obtained.
Key exclusion criteria1. Patients with an isolated urostomy
2. Life expectancy less than 12 months
3. Proposed treatment plan for dealing with PSH involves restoration of gut continuity meaning that patient will have no stoma after treatment.
4. Anyone who does not have an email address or does not have access to the internet or a smart device
Date of first enrolment21/08/2023
Date of final enrolment09/08/2025

Locations

Countries of recruitment

  • England
  • United Kingdom

Study participating centres

Queen Elizabeth Hospital Birmingham
Mindelsohn Way
Edgbaston
Birmingham
B15 2WB
United Kingdom
Royal Devon and Exeter Hospital
Royal Devon & Exeter Hospital
Barrack Road
Exeter
EX2 5DW
United Kingdom
Leicester Royal Infirmary
Infirmary Square
Leicester
LE1 5WW
United Kingdom
Manchester Royal Infirmary
Cobbett House
Manchester Royal Infirmary
Oxford Road
Manchester
M13 9WL
United Kingdom
Royal Lancaster Infirmary
Medical Wards
Ashton Road
Lancaster
LA1 4RP
United Kingdom
Royal Victoria Infirmary
Queen Victoria Road
Newcastle upon Tyne
NE1 4LP
United Kingdom
Salisbury District Hospital
Salisbury District Hospital
Odstock Road
Salisbury
SP2 8BJ
United Kingdom
St Peters Hospital
Guildford Road
Chertsey
KT16 0PZ
United Kingdom
Stoke Mandeville Hospital
Mandeville Road
Aylesbury
HP21 8AL
United Kingdom
York Hospital
Wigginton Road
York
YO31 8HE
United Kingdom
Bedford Hospital South
Kempston Road
Bedford
MK42 9DJ
United Kingdom
Broomfield Hospital
Court Road
Broomfield
Chelmsford
CM1 7ET
United Kingdom
Northern General Hospital
Northern General Hospital NHS Trust
C Floor, Huntsmnan Building
Herries Road
Sheffield
S5 7AU
United Kingdom
University Hospital Coventry & Warwickshire
Clifford Bridge Road
Walsgrave
Coventry
CV2 2DX
United Kingdom
Warwick Hospital
Lakin Road
Warwick
CV34 5BW
United Kingdom
Royal Cornwall Hospital (treliske)
Treliske
Truro
TR1 3LJ
United Kingdom
Blackpool Victoria Hospital
Whinney Heys Road
Blackpool
FY3 8NR
United Kingdom
Russells Hall Hospital
Pensnett Road
Dudley
DY1 2HQ
United Kingdom

Sponsor information

University of Birmingham
Hospital/treatment centre

Edgbaston
Birmingham
B15 2TT
England
United Kingdom

Email researchgovernance@contacts.bham.ac.uk
Website http://www.birmingham.ac.uk/index.aspx
ROR logo "ROR" https://ror.org/03angcq70

Funders

Funder type

Charity

Bowel Research UK
Government organisation / Trusts, charities, foundations (both public and private)
Alternative name(s)
Bowel Research United Kingdom, BRUK
Location
United Kingdom
European Society of Coloproctology
Private sector organisation / Associations and societies (private and public)
Alternative name(s)
The European Society of COLOPROCTOLOGY, European Society of Coloprotology, ESCP
Location
United Kingdom

Results and Publications

Intention to publish date15/08/2029
Individual participant data (IPD) Intention to shareNo
IPD sharing plan summaryData sharing statement to be made available at a later date
Publication and dissemination planPlanned publication in a high-impact peer-reviewed journal around one year after the study end date. We will also publicise the results on the study’s website: www.escp.eu.com/research/cohort-studies/2019-patient-reported-outcomes-after-parastomal-hernia-treatment. No individual patients will be identifiable in any publications.
IPD sharing planThe data-sharing plans for the current study are unknown and will be made available at a later date.

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?
Participant information sheet version 5.0 21/06/2023 03/08/2023 No Yes

Additional files

43966_PIS_v5.0_21Jun2023.pdf

Editorial Notes

21/08/2023: The recruitment start date has been changed from 17/08/2023 to 21/08/2023.
18/08/2023: Internal review.
17/07/2023: Trial's existence confirmed by the National Institute for Health and Care Research (NIHR) (UK).